The Rising Consumption of Alcohol Leading To Severe Liver Diseases and Will Create a Significant Growth Opportunity For Global Autoimmune Hepatitis Diagnosis And Treatment Market

The global autoimmune hepatitis diagnosis and treatment Market system market is anticipated to grow at a considerable CAGR of around 5.7% during the forecast period (2021-2027). The increasing consumption of alcohol by both males and females is the major reason for the damage of the liver increasing the demand for autoimmune hepatitis diagnosis and treatment. For instance, according to National Institute on Alcohol Abuse and Alcoholism (NIAAA), in 2019, alcohol was involved in 43.1% of the 85,688 liver disease mortalities among people aged 12 and above. In which among males, 53,486 liver disease mortalities occurred, with alcohol accounting for 45.6% of the cases. On the other hand, among females, 32,202 liver disease deaths occurred with alcohol accounting for 39.0% of the cases.

Browse the full report description Global Autoimmune Hepatitis Diagnosis and Treatment Market Size, Share & Trends Analysis Report By Diagnosis ( Blood Test, Imaging Test, Liver Biopsy) By Treatment ( Medication, Corticosteroids, Immune System Suppressors, Liver Transplant), By Type (Type-I, Type-II, Variant AIH) End-User (Hospitals & Clinics, Diagnostic Centre, and Research Institutions) Forecast Period 2021-2027 at https://www.omrglobal.com/industry-reports/autoimmune-hepatitis-diagnosis-and-treatment-market

Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in August 2020, GlaxoSmithKline plc in Phase II clinical trial, GSK'836 (GSK3228836), a candidate for chronic hepatitis B treatment, looked promising. Following four weeks of treatment, the drug candidate resulted in a decrease in hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA compared with placebo. These findings are analysed based on 31 chronic hepatitis B patients who were receiving stable nucleoside or nucleotide analogue (NA) treatment. With the help of GSK'836, the company will be able to provide functional care at an early stage by reducing the risk of liver-related complications and liver cancer.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Diagnosis

o By Treatment

o By Type

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Gilead Lifesciences, Inc., Merck & Co., Inc., Bio-Rad Laboratories, Inc. Novartis International AG, Abbott Laboratories, Inc.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Autoimmune Hepatitis Diagnosis and Treatment Market Report Segment

By Diagnosis

• Blood Test
• Imaging Test
• Liver Biopsy

By Treatment

• Medication
• Corticosteroids 
• Immune System Suppressors
• Liver Transplant

By Type

• Type-I
• Type-II
• Variant AIH

By End-User

• Hospitals and Clinics
• Diagnostic Centre
• Research Institutions

Global Autoimmune Hepatitis Diagnosis and Treatment Market Report Segment by Region